NASDAQ:CLDX - Celldex Therapeutics Stock Price, Forecast & News

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Shares of Celldex Therapeutics reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.75) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.84) by $0.09. The biopharmaceutical company earned $0.55 million during the quarter, compared to analyst estimates of $1.26 million. Celldex Therapeutics had a negative return on equity of 43.03% and a negative net margin of 1,119.84%. View Celldex Therapeutics' Earnings History.

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Celldex Therapeutics.

2 Wall Street analysts have issued twelve-month target prices for Celldex Therapeutics' stock. Their forecasts range from $8.00 to $19.00. On average, they anticipate Celldex Therapeutics' share price to reach $13.50 in the next twelve months. This suggests a possible upside of 339.7% from the stock's current price. View Analyst Price Targets for Celldex Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celldex Therapeutics.

News headlines about CLDX stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Celldex Therapeutics earned a daily sentiment score of -1.9 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Celldex Therapeutics.

Some companies that are related to Celldex Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include Opko Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Intrexon (XON), Micron Technology (MU), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Dynavax Technologies (DVAX) and bluebird bio (BLUE).

Celldex Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (6.91%), TSP Capital Management Group LLC (2.21%) and Acadian Asset Management LLC (1.54%). Company insiders that own Celldex Therapeutics stock include James J Marino and Tibor Keler. View Institutional Ownership Trends for Celldex Therapeutics.

CLDX stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for Celldex Therapeutics.

CLDX stock was acquired by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC and Renaissance Technologies LLC. Company insiders that have bought Celldex Therapeutics stock in the last two years include James J Marino and Tibor Keler. View Insider Buying and Selling for Celldex Therapeutics.

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLDX stock can currently be purchased for approximately $3.07.

Celldex Therapeutics has a market capitalization of $49.52 million and generates $9.54 million in revenue each year. The biopharmaceutical company earns $-151,180,000.00 in net income (profit) each year or ($6.82) on an earnings per share basis. Celldex Therapeutics employs 133 workers across the globe.View Additional Information About Celldex Therapeutics.

The official website for Celldex Therapeutics is http://www.celldex.com/.

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]